Related references
Note: Only part of the references are listed.Endogenous hyperinsulinaemia and exogenous insulin: A common theme between atherosclerosis, increased cancer risk and other morbidities
Sarah E. Holden et al.
ATHEROSCLEROSIS (2012)
Weight changes and their predictors amongst 11 140 patients with type 2 diabetes in the ADVANCE trial
S. van Dieren et al.
DIABETES OBESITY & METABOLISM (2012)
Clinical Importance of Assessment of Type 2 Diabetes Mellitus with Visceral Obesity. A Japanese Perspective
Ken Kishida et al.
CURRENT DIABETES REVIEWS (2012)
The Risk of Overall Mortality in Patients With Type 2 Diabetes Receiving Glipizide, Glyburide, or Glimepiride Monotherapy A retrospective analysis
Kevin M. Pantalone et al.
DIABETES CARE (2010)
Changes in Serum Adiponectin Concentrations Correlate With Changes in BMI, Waist Circumference, and Estimated Visceral Fat Area in Middle-Aged General Population
Y. Okauchi et al.
DIABETES CARE (2009)
Low-dose pioglitazone increases serum high molecular weight adiponectin and improves glycemic control in Japanese patients with poorly controlled type 2 diabetes
Yoshimasa Aso et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2009)
Effects of sulfonylurea drugs on adiponectin production from 3T3-L1 adipocytes: Implication of different mechanism from pioglitazone
Yukiko Kanda et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2008)
Comparison of the effects of pioglitazone and voglibose on circulating total and high-molecular-weight adiponectin, and on two fibrinolysis inhibitors, in patients with Type 2 diabetes
Y. Aso et al.
DIABETIC MEDICINE (2007)
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Steven E. Kahn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome
Takashi Kadowaki et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Efficacy of glimepiride in patients with poorly controlled insulin-treated type 2 diabetes mellitus
H Ose et al.
ENDOCRINE JOURNAL (2005)
Sulfonylurea agents exhibit peroxisome proliferator-activated receptor γ agonistic activity
S Fukuen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Glimepiride enhances intrinsic peroxisome proliferator-activated receptor-γ activity in 3T3-L1 adipocytes
K Inukai et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Sulfonylurea treatment of type 2 diabetes mellitus: Focus on glimepiride
MT Korytkowski
PHARMACOTHERAPY (2004)
The role of glimepiride in the effective management of Type 2 diabetes
SN Davis
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2004)
Impaired multimerization of human adiponectin mutants associated with diabetes - Molecular structure and multimer formation of adiponectin
H Waki et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Effect of glimepiride on serum adiponectin level in subjects with type 2 diabetes
S Nagasaka et al.
DIABETES CARE (2003)
Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects
T Tsunekawa et al.
DIABETES CARE (2003)
Glimepiride and serum adiponectin level in type 2 diabetic subjects - Response
S Nagasaka et al.
DIABETES CARE (2003)
The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects
JG Yu et al.
DIABETES (2002)
Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide
MM Mocanu et al.
CIRCULATION (2001)
Share Paper
